Table 2.

Lanreotide depot dose (n, %) at enrollment and after 12 months of treatment

	Patient always	Partner always	HCP always	Combination/other
Dose at enrollment (mg)	n = 26	n = 41	n = 58	n = 41	All patients (n = 166)
60	1 (4)	6 (15)	11 (19)	9 (22)	27 (16)
90	18 (69)	24 (59)	29 (50)	23 (56)	94 (57)
120	7 (27)	11 (27)	18 (31)	9 (22)	45 (27)

Dose at 12 months (mg)	n = 23	n = 38	n = 50	n = 35	All patients (n = 146)
60	1 (4)	6 (16)	7 (14)	7 (20)	21 (14)
90	10 (44)	19 (50)	21 (42)	12 (34)	62 (43)
120	12(53)	13 (34)	22 (44)	15 (43)	62 (43)